D. Copeland

发表

Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy

R. Scheule, J. Shayman, W. Chuang, 2010, Journal of Inherited Metabolic Disease.

Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice

J. Shayman, Seng H. Cheng, Canwen Jiang, 2009, Hepatology.

Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.

H. Overkleeft, A. Meijer, N. Yew, 2010, Journal of medicinal chemistry.

Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice.

R. Scheule, K. Ashe, Christopher G. F. Cooper, 2012, Molecular genetics and metabolism.

Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease

J. M. Aerts, R. Scheule, K. Ashe, 2011, PloS one.

Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease

R. Desnick, R. Scheule, J. Shayman, 2010, PloS one.

Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease

R. Scheule, Seng H. Cheng, W. Weber, 2012, PloS one.

A Glucosylceramide Synthase Inhibitor Protects Rats Against the Cytotoxic Effects of Shiga Toxin 2

C. Silberstein, E. Zotta, D. Copeland, 2011, Pediatric Research.

A Glucosylceramide Synthase Inhibitor Prevents the Cytotoxic Effects of Shiga Toxin-2 on Human Renal Tubular Epithelial Cells

C. Silberstein, D. Copeland, C. Ibarra, 2009 .

Search for the optimal fetal cell antibody: results of immunophenotyping studies using flow cytometry

Yun-Ling Zheng, R. Wapner, D. Bianchi, 1997, Human Genetics.

Measurement of lysosomal glucocerebrosidase activity in mouse liver using a fluorescence-activated cell sorter assay.

Kenneth P. Karey, L. Andrews, D. Copeland, 2004, Analytical biochemistry.

A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.

J. Shayman, W. Chuang, J. Marshall, 2007, Molecular genetics and metabolism.

Viability of Escherichia coli treated with colicin K.

J. E. Lusk, D. Copeland, A. Kopecky, 1975, Proceedings of the National Academy of Sciences of the United States of America.

The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function.

K. Klinger, M. Goldberg, B. Teicher, 2011, International journal of oncology.